News Channels

07 Mar 2017 New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis
07 Mar 2017 Staten Biotechnology exercises option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia from argenx N.V.
07 Mar 2017 Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL
07 Mar 2017 New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
07 Mar 2017 TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)
07 Mar 2017 Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies
07 Mar 2017 Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
07 Mar 2017 Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)
07 Mar 2017 Concert Pharmaceuticals Presents CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting
07 Mar 2017 Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy
07 Mar 2017 FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine
07 Mar 2017 Deciphera Pharmaceuticals Initiates a Phase 1 Clinical Trial of DCC-3014 in Patients with Advanced Malignancies
07 Mar 2017 Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
04 Mar 2017 LEO Pharma Announces Positive Results From Phase 2b Clinical Study for Tralokinumab in Atopic Dermatitis
04 Mar 2017 SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request
04 Mar 2017 Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
04 Mar 2017 Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
04 Mar 2017 FDA approves first treatment for frequent urination at night due to overproduction of urine
03 Mar 2017 NEMUS Bioscience and Catalent to Advance NB1222 into Human Dosage Formulation Development
03 Mar 2017 Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing